(0.32%) 5 116.09 points
(0.32%) 38 363 points
(0.35%) 15 983 points
(-0.94%) $83.06
(5.56%) $2.03
(0.33%) $2 355.00
(0.42%) $27.65
(4.03%) $959.25
(-0.25%) $0.932
(-0.40%) $10.98
(-0.56%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases...
Stats | |
---|---|
本日の出来高 | 1 496.00 |
平均出来高 | 2 825.00 |
時価総額 | 8.35M |
EPS | $0 ( 2024-03-27 ) |
次の収益日 | ( $0 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.570 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Chicko Rhonda M. | Sell | 0 | Common Stock |
2024-01-01 | Hecht Peter M | Buy | 15 000 | Common Stock |
2024-01-01 | Graul Regina Margaret | Buy | 50 000 | Common Stock |
2023-11-30 | Katabi Dina | Sell | 0 | Common Stock |
2023-11-30 | Higgins Michael J | Sell | 0 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 100 transactions |
Buy: 5 326 508 | Sell: 727 933 |
Cyclerion Therapeutics 相関
10 最も負の相関 | |
---|---|
SMH | -0.909 |
ATVI | -0.898 |
VTRU | -0.894 |
SGLB | -0.892 |
PT | -0.89 |
BEEM | -0.889 |
ALDX | -0.886 |
ADTN | -0.885 |
BSET | -0.882 |
VIASP | -0.878 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Cyclerion Therapeutics 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-8.99 |
FY | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-8.99 |
FY | 2022 |
収益: | $297 000 |
総利益: | $232 000 (78.11 %) |
EPS: | $-20.15 |
FY | 2021 |
収益: | $3.94M |
総利益: | $3.94M (100.00 %) |
EPS: | $-1.193 |
Financial Reports:
No articles found.
Cyclerion Therapeutics
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。